Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Prepaid Assets (2017 - 2026)

Cogent Biosciences' Prepaid Assets history spans 10 years, with the latest figure at $11.4 million for Q1 2026.

  • Quarterly Prepaid Assets rose 58.18% to $11.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $11.4 million through Mar 2026, up 58.18% year-over-year, with the annual reading at $9.6 million for FY2025, 2.08% up from the prior year.
  • Prepaid Assets came in at $11.4 million for Q1 2026, up from $9.6 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $11.4 million in Q1 2026 to a low of $3.7 million in Q1 2022.
  • The 5-year median for Prepaid Assets is $6.2 million (2024), against an average of $6.5 million.
  • Year-over-year, Prepaid Assets soared 177.14% in 2022 and then decreased 13.06% in 2024.
  • Cogent Biosciences' Prepaid Assets stood at $4.4 million in 2022, then increased by 14.11% to $5.1 million in 2023, then skyrocketed by 85.64% to $9.4 million in 2024, then grew by 2.08% to $9.6 million in 2025, then rose by 19.13% to $11.4 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Prepaid Assets are $11.4 million (Q1 2026), $9.6 million (Q4 2025), and $6.4 million (Q3 2025).